Pfizer Wins Appeal Over Neurontin

Law360, New York (September 21, 2007, 12:00 AM EDT) -- Pfizer Inc. has promised to seek “full compensation” against generic drug manufacturers after a U.S. appellate court resuscitated Pfizer’s patent infringement suit over its blockbuster epilepsy drug Neurontin, which had earned the company more than $2 billion a year.

The U.S. Court of Appeals for the Federal Circuit ruled on Friday that the U.S. District Court for the District of New Jersey had erroneously granted summary judgment for the generic drug makers, which include Teva Pharmaceutical Industries Ltd., Apotex Inc. and Novartis subsidiary Eon Labs Manufacturing...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.